La ricerca clinica di Fondazione NIBIT

Oggi la ricerca in ambito oncologico è caratterizzata dall’avvio di numerose sperimentazioni cliniche volte a valutare l’efficacia di nuove molecole o combinazioni terapeutiche. Fondazione NIBIT dalla sua nascita ad oggi ha partecipato a numerosi clinical trials. Ecco l’elenco di quelli in corso:

1) A single arm, phase II clinical study of anti-CTLA-4 tremelimumab combined with the anti-PD-L1 monoclonal antibody durvalumab in patients with unresectable malignant mesothelioma: the NIBIT-MESO-1 study (NCT02588131)

2) A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab and the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 study (NCT02460068)

3) A phase 1b, open-label, dose escalation study investigating different doses of SGI-110 in combination with ipilimumab in unresectable or metastatic melanoma patients: the NIBIT-M4 study (NCT02608437)

4) A randomized phase 1b, run-in, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PDL1: the NIBIT-ML1 study (EUDRACT 2019 – 002986-36)

5) A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1: the NIBIT-ML1 study (NCT04250246) scarica qui il documento di presentazione